scholarly journals Effect of an Endothelin Receptor Antagonist and an Angiotensin Converting Enzyme Inhibitor on Metabolism and Contraction in the Ischemic and Reperfused Rabbit Heart

1999 ◽  
Vol 63 (10) ◽  
pp. 770-774 ◽  
Author(s):  
Hitoshi Kawabata ◽  
Teruhiko Ryomoto ◽  
Kinji Ishikawa
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Receptor Antagonist ◽  
Angiotensin Converting Enzyme Inhibitor ◽  
Enzyme Inhibitor ◽  
Rabbit Heart ◽  
Endothelin Receptor Antagonist ◽  
Endothelin Receptor ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitor

scholarly journals Icatibant in the Treatment of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema

2014 ◽  
Vol 2014 ◽  
pp. 1-3 ◽  
Author(s):  
Neil H. Crooks ◽  
Jaimin Patel ◽  
Lavanya Diwakar ◽  
Fang Gao Smith
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Airway Obstruction ◽  
Receptor Antagonist ◽  
Angiotensin Converting Enzyme Inhibitor ◽  
Enzyme Inhibitor ◽  
Therapeutic Option ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitor ◽  
The United Kingdom ◽  
Novel Therapeutic

We describe the case of a 75-year-old woman who presented with massive tongue and lip swelling secondary to angiotensin-converting enzyme inhibitor-induced angioedema. An awake fibre-optic intubation was performed because of impending airway obstruction. As there was no improvement in symptoms after 72 hours, the selective bradykinin B2 receptor antagonist icatibant (Firazyr) was administered and the patient’s trachea was successfully extubated 36 hours later. To our knowledge this is the first documented case of icatibant being used for the treatment of angiotensin-converting enzyme inhibitor-induced angioedema in the United Kingdom and represents a novel therapeutic option in its management.

Sign in / Sign up

Export Citation Format

Share Document